Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin therapeutic monitoring: trough-based versus AUC/MIC-guided dosing for acute kidney injury risk
RBR-2t2t5x9Recruiting
- Sponsor
- Santa Marcelina Saúde
- Start
- May 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vancomycin in Staphylococcosis, Gram-positive bacterial infection and septic shock (2 arms), sponsored by Santa Marcelina Saúde. Primary endpoint: Acute kidney injury risk. Started May 2026; status: recruiting.
02
Drugs
vancomycin
03
Conditions
StaphylococcosisGram-positive bacterial infectionseptic shock
Beyond the preview
Go deeper on RBR-2t2t5x9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2t2t5x9.